Elite Pharmaceuticals INC: directors' dealings · United States · SEC (Form 4)

About Elite Pharmaceuticals INC

Elite Pharmaceuticals, Inc. (ELTP) is a United States pharmaceutical company whose shares are traded in the U.S. on a NASDAQ/NYSE-type market. The company is based in Northvale, New Jersey, and was incorporated in 1997 under Delaware law. Elite has built its business around niche generic pharmaceuticals, while historically also pursuing branded development programs under NDA pathways. In its recent SEC disclosures, the company states that it focuses on manufacturing approved ANDA-based generic products, developing additional generic candidates, and advancing selected pipeline products through partnerships, licensing, co-development, and related commercialization arrangements. Elite also disclosed that it has paused further development of NDA programs, signaling a more focused capital allocation strategy and a stronger emphasis on near- to medium-term commercial opportunities. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001053369/000149315226007104/form10-q.htm?utm_source=openai)) From a competitive standpoint, Elite is best described as a specialty pharmaceutical player rather than a large integrated drugmaker. Its edge lies in operating in narrower product markets where formulation complexity, regulatory know-how, and timing of launches can matter as much as scale. The company’s model combines its own-label sales with licensing and collaboration structures, which can broaden reach while helping spread development risk. Its core commercial footprint is the United States, which is also the key regulatory market for its portfolio. That domestic focus simplifies the narrative for investors but also means the company remains highly exposed to U.S. FDA approvals, pricing dynamics, and generic competition. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1053369/000164117225017134/form10-k.htm?utm_source=openai)) Recent operating news has been constructive. For the fiscal year ended March 31, 2025, Elite reported revenue of $84.0 million, up about 48% year over year, and operating profit of $19.6 million, up about 81% versus the prior year. Management attributed the improvement mainly to sales of lisdexamfetamine products launched during fiscal 2025 and to strong growth in Elite label product lines introduced in the previous fiscal year. For investors, this indicates a business that is increasingly benefiting from product launches and commercialization momentum rather than relying solely on long-duration development milestones. In short, ELTP remains a U.S.-listed small-cap pharma name with a concentrated generic-specialty profile, improving operating leverage, and a business model tied closely to execution in the United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1053369/000164117225017151/ex99-1.htm?utm_source=openai))